FDC Medicines

Optical fibre cable (OFC) manufacturers are bracing to meet a multifold increase in fiberisation, aggressively tap global markets to power 5G services, and cope with demand from fibre-to-the home

The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants

CDSCO aims to phase out these combinations and codeine-based drugs in a phased manner

Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients. "We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement. The drug maker is the first company in India to market the FDC of .

In September last year, the government had banned around 328 Fixed Dose Combination (FDC) drugs, citing lack of therapeutic justification

The apex court set aside the order of the Delhi High Court which had quashed the Centre's decision to ban these drugs on the ground that requisite procedure prescribed in the Drugs and Cosmetics Act,